12 Month Price Forecast For GALT
Distance to GALT Price Forecasts
GALT Price Momentum
🤔 Considering Galectin (GALT)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: December 13, 2024 12:37 PM UTC
GALT Analyst Ratings & Price Targets
Based on our analysis of 3 Wall Street analysts, GALT has a consensus that is bullish. The median price target is $11.00, with forecasts ranging from $11.00 to $11.00. Currently, there are 1 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
With GALT currently trading at $1.99, the median price forecast suggests a 452.8% upside. The most optimistic forecast comes from Ed Arce at HC Wainwright & Co., projecting a 452.8% upside, while Ed Arce at HC Wainwright & Co. provides the most conservative target, suggesting a 452.8% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
GALT Analyst Consensus
GALT Price Target Range
Latest GALT Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for GALT.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 15, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $11.00 |
| Aug 16, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $11.00 |
| Apr 9, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $11.00 |
| Apr 1, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $11.00 |
| Aug 15, 2023 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $11.00 |
| May 17, 2023 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $11.00 |
| Mar 3, 2023 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $11.00 |
| May 17, 2022 | HC Wainwright & Co. | Ed Arce | Buy | Maintains | $11.00 |
| Apr 16, 2021 | HC Wainwright & Co. | Ed Arce | Buy | Maintains | $14.00 |
| Aug 13, 2020 | HC Wainwright & Co. | Buy | Maintains | $12.00 | |
| Apr 3, 2020 | B. Riley Securities | Mayank Mamtani | Buy | Maintains | $4.00 |
| Apr 3, 2020 | B. Riley FBR | Buy | Maintains | $0.00 | |
| Mar 17, 2020 | HC Wainwright & Co. | Ed Arce | Buy | Maintains | $9.00 |
| Feb 13, 2019 | B. Riley FBR | Buy | Initiates | $0.00 | |
| Feb 13, 2019 | B. Riley Securities | Buy | Initiates | $0.00 | |
| Oct 19, 2017 | Roth Capital | Buy | Initiates | $0.00 | |
| Oct 6, 2017 | Seaport Global | Buy | Initiates | $0.00 | |
| Mar 30, 2017 | HC Wainwright & Co. | Buy | Upgrade | $0.00 | |
| Mar 30, 2017 | H.C. Wainwright | Buy | Upgrade | $0.00 | |
| Oct 3, 2016 | FBR Capital | Market Perform | Downgrade | $0.00 |
Galectin Therapeutics Inc (GALT) Financial Data
Galectin Therapeutics Inc has a market capitalization of $121.13M with a P/E ratio of -2.7x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of +74.4%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
Galectin Therapeutics Inc (GALT) Company Overview
About Galectin Therapeutics Inc
Develops therapies for fibrotic and cancer diseases.
Galectin Therapeutics focuses on researching and developing novel therapies targeting galectin-3, particularly for conditions like NASH cirrhosis and liver fibrosis. The company generates potential revenue through the advancement of its clinical-stage product candidates, including its lead drug belapectin, which is currently undergoing multiple Phase 2 and 3 clinical trials.
Founded in 2000 and based in Norcross, Georgia, Galectin Therapeutics operates through a joint venture with SBH Sciences to innovate small organic molecule inhibitors for oral use. The company, originally named Pro-Pharmaceuticals, Inc., rebranded in 2011 to reflect its focus on galectin-targeted therapies.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
14
CEO
Mr. Joel Lewis
Country
United States
IPO Year
2002
Website
galectintherapeutics.comGalectin Therapeutics Inc (GALT) Latest News & Analysis
Here's Why Galectin Therapeutics (GALT) is Poised for a Turnaround After Losing -31.83% in 4 Weeks
4 days agoGalectin Therapeutics (GALT) is in oversold territory, with strong analyst consensus for higher earnings estimates, suggesting a potential trend reversal.
Galectin Therapeutics (GALT) may be poised for a rebound due to oversold conditions and upward revisions in earnings estimates from analysts, signaling potential value for investors.
Galectin Therapeutics Presents Three Abstracts at the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting
25 days agoGalectin Therapeutics, Inc. (NASDAQ: GALT) presented three posters on its NAVIGATE trial for MASH cirrhosis and portal hypertension at the AASLD annual meeting from November 15-19, 2024.
Galectin Therapeutics' presentation at a major medical conference highlights progress in its NAVIGATE trial, potentially influencing stock performance and investor sentiment around its drug development.
Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2024 and Provides Business Update
29 days agoGalectin Therapeutics (NASDAQ: GALT) reported Q3 2024 results, focusing on the NAVIGATE trial for belapectin in MASH cirrhosis. Topline results are expected next month, addressing a significant medical need.
Galectin Therapeutics' progress on the NAVIGATE trial and potential new treatment for cirrhosis could significantly impact stock value, driven by investor anticipation of positive trial results.
Galectin Therapeutics Announces Acceptance of Three Abstracts for the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting
1 month agoGalectin Therapeutics, Inc. (NASDAQ: GALT) will present three abstracts from its NAVIGATE trial at the AASLD's annual meeting in San Diego, November 15-19, 2024.
The acceptance of Galectin Therapeutics' trial abstracts at a major medical conference boosts credibility and visibility, potentially influencing stock performance and investor sentiment.
Galectin Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
3 months agoGalectin Therapeutics, Inc. (NASDAQ: GALT) will have CEO Joel Lewis and CMO Khurram Jamil attend the H.C. Wainwright 26th Annual Global Investment Conference from September 9-11, 2024.
Leadership attendance at a major investment conference can enhance visibility, potentially attract investment, and signal company confidence in growth prospects, impacting stock performance.
Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2024 and Provides Business Update
4 months agoGalectin Therapeutics, Inc. (NASDAQ: GALT) reported its financial results and business update for Q2 2024, ending June 30. Further details on performance will be available in the full report.
Galectin Therapeutics' financial results and business update could influence stock performance, affecting investor sentiment and potential market value.
Frequently Asked Questions About GALT Stock
What is Galectin Therapeutics Inc's (GALT) stock forecast for 2025?
Based on our analysis of 3 Wall Street analysts, Galectin Therapeutics Inc (GALT) has a median price target of $11.00. The highest price target is $11.00 and the lowest is $11.00.
Is GALT stock a good investment in 2025?
According to current analyst ratings, GALT has 1 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.99. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for GALT stock?
Wall Street analysts predict GALT stock could reach $11.00 in the next 12 months. This represents a 452.8% increase from the current price of $1.99. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Galectin Therapeutics Inc's business model?
Galectin Therapeutics focuses on researching and developing novel therapies targeting galectin-3, particularly for conditions like NASH cirrhosis and liver fibrosis. The company generates potential revenue through the advancement of its clinical-stage product candidates, including its lead drug belapectin, which is currently undergoing multiple Phase 2 and 3 clinical trials.
What is the highest forecasted price for GALT Galectin Therapeutics Inc?
The highest price target for GALT is $11.00 from Ed Arce at HC Wainwright & Co., which represents a 452.8% increase from the current price of $1.99.
What is the lowest forecasted price for GALT Galectin Therapeutics Inc?
The lowest price target for GALT is $11.00 from Ed Arce at HC Wainwright & Co., which represents a 452.8% increase from the current price of $1.99.
What is the overall GALT consensus from analysts for Galectin Therapeutics Inc?
The overall analyst consensus for GALT is bullish. Out of 3 Wall Street analysts, 1 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $11.00.
How accurate are GALT stock price projections?
Stock price projections, including those for Galectin Therapeutics Inc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
